Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERVEBO Vaccine Immune Response in Ebola Survivors vs Controls
NCT05992480Phase 4Active, not recruiting
- Sponsor
- Tulane University
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by Tulane University. Primary endpoints: Immunogenicity and durability of rVSVDG-ZEBOV-GP at 6 months and Incidence of adverse events at 6 months. Started Dec 2025; status: active, not recruiting.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT05992480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992480.